Inosine

Overview

A purine nucleoside that has hypoxanthine linked by the N9 nitrogen to the C1 carbon of ribose. It is an intermediate in the degradation of purines and purine nucleosides to uric acid and in pathways of purine salvage. It also occurs in the anticodon of certain transfer RNA molecules. (Dorland, 28th ed)

Indication

The primary popular claim made for inosine, that it enhances exercise and athletic performance, is refuted by the available research data. There is some preliminary evidence that inosine may have some neurorestorative, anti-inflammatory, immunomodulatory and cardioprotective effects.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer	2024/04/09	NCT06355024	Phase 2	Not yet recruiting	Fudan University
Inhaled Nitric Oxide in Acute Ischemic Stroke Patients Undergoing Mechanical Thrombectomy	2023/05/23	NCT05871606	Phase 1	Not yet recruiting	Wake Forest University Health Sciences
Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors	2023/04/12	NCT05809336	Phase 2	Completed	Beijing Friendship Hospital
Pulsed Inhaled Nitric Oxide for the Treatment of Patients With Mild or Moderate COVID-19	2020/04/24	NCT04358588	N/A	NO_LONGER_AVAILABLE	Bellerophon
Study of PAH Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled Nitric	2018/07/27	NCT03602781	Phase 3	Withdrawn	Bellerophon Pulse Technologies
Inosine 5'-Monophosphate to Raise of Serum Uric Acid Level in Patients With Multiple System Atrophy: a Multi-center, Randomized Controlled, Double Blind, Parallel Assigned Clinical Trial	2018/01/18	NCT03403309	Phase 2	Completed	Yonsei University
Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS)	2017/05/30	NCT03168711	Phase 2	Completed	Massachusetts General Hospital
Inhaled Selective Pulmonary Vasodilators for Advanced Heart Failure Therapies and Lung Transplantation Outcomes	2017/03/15	NCT03081052	Phase 4	Completed	Duke University
Runihol in Nonalcoholic Fatty Liver Disease and Metabolic Syndrome	2016/10/12	NCT02930161	Phase 2	Terminated	POLYSAN Scientific & Technological Pharmaceutical Company
Study of Urate Elevation in Parkinson's Disease, Phase 3	2015/12/30	NCT02642393	Phase 3	Completed	Michael Alan Schwarzschild

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
Rejuvesol	Citra Labs, LLC	23731-7000	EXTRACORPOREAL	1.34 g in 50 mL	2/14/2023

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
Inosine Granules	广州白云山汉方现代药业有限公司	国药准字H44025153	化学药品	颗粒剂	9/25/2019
Inosine Granules	药都制药集团股份有限公司	国药准字H13024469	化学药品	颗粒剂	6/29/2020
Inosine Granules	湖北美宝药业股份有限公司	国药准字H42022914	化学药品	颗粒剂	8/27/2020
Inosine Granules	石家庄宇惠制药有限公司	国药准字H13024468	化学药品	颗粒剂	4/25/2021
Inosine Granules	华润三九（北京）药业有限公司	国药准字H11022436	化学药品	颗粒剂	11/27/2020
Inosine Granules	海南制药厂有限公司制药一厂	国药准字H20046209	化学药品	颗粒剂	6/17/2020
Inosine and Glucose Injection	江苏晨牌药业集团股份有限公司	国药准字H20020107	化学药品	注射剂	8/11/2020
Inosine and Glucose Injection	广东彼迪药业有限公司	国药准字H20050928	化学药品	注射剂	9/12/2019
Inosine and Glucose Injection	青州尧王制药有限公司	国药准字H20030534	化学药品	注射剂	6/29/2020
Inosine and Glucose Injection	新疆华世丹药业股份有限公司	国药准字H20040174	化学药品	注射剂	12/14/2020

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
THE GROWLING DOG ENERGY MIX oral powder jar/can	51968	Musashi Pty Ltd	Medicine	A	3/23/1995

AI-Powered Research

Premium Access